hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
== Health == Domestic kittens in developed societies are usually vaccinated against common illnesses from two to three months of age. The usual combination vaccination protects against feline viral rhinotracheitis (FVR), feline calicivirus (C), and feline panleukopenia (P). This FVRCP inoculation is usually given at eight, twelve, and sixteen weeks, and an inoculation against rabies may be given at sixteen weeks. Kittens are usually spayed or neutered at seven months of age, but kittens may be neutered as young as seven weeks (if large enough), especially in animal shelters. Such early neutering does not appear to have any long-term health risks for cats, and it may even be beneficial in male cats. Kittens are commonly given deworming treatments for roundworms from about four weeks.
Any floating object displaces its own weight of fluid. In other words, for an object floating on a liquid surface (like a boat) or floating submerged in a fluid (like a submarine in water or dirigible in air) the weight of the displaced fluid equals the weight of the object. Thus, only in the special case of floating does the buoyant force acting on an object equal the objects weight. Consider a 1-ton block of solid iron. As iron is nearly eight times as dense as water, it displaces only 1/8 ton of water when submerged, which is not enough to keep it afloat. Suppose the same iron block is reshaped into a bowl. It still weighs 1 ton, but when it is put in water, it displaces a greater volume of water than when it was a block. The deeper the iron bowl is immersed, the more water it displaces, and the greater the buoyant force acting on it. When the buoyant force equals 1 ton, it will sink no farther. When any boat displaces a weight of water equal to its own weight, it floats. This is often called the "principle of flotation": A floating object displaces a weight of fluid equal to its own weight. Every ship, submarine, and dirigible must be designed to displace a weight of fluid at least equal to its own weight. A 10,000-ton ship's hull must be built wide enough, long enough and deep enough to displace 10,000 tons of water and still have some hull above the water to prevent it from sinking. It needs extra hull to fight waves that would otherwise fill it and, by increasing its mass, cause it to submerge.
Most players accepted the provisional suspensions immediately; Dustin Fletcher and Jobe Watson both participated in the 2014 International Rules Series test match on 22 November before beginning their suspensions; Alwyn Davey and Leroy Jetta, neither of whom was on the Essendon list any longer, both opted to play the 2014/15 Northern Territory Football League season (which runs over the Australian summer), and did not begin their provisional suspensions until February 2015. After the tribunal hearings were complete, it was announced that a final decision was expected in late March. This meant that the thirty-four players, including seventeen still at Essendon, would be under provisional suspension during the 2015 NAB Challenge pre-season matches. All twenty-five Essendon players who were at the club during the supplements program received permission to miss the series, including eight players who were not facing charges but were permitted to stand aside to protect their teammates' anonymity; of those eight players, four elected to play. Essendon was given permission to field VFL-listed players from its reserves team, and to sign players from state leagues to temporary contracts to serve as top-up players during the NAB Challenge. On 31 March, the week before the opening of the 2015 AFL season, the tribunal announced that it had found the 34 players not guilty. The tribunal confirmed that Thymosin beta-4 was a banned substance during the program, but that it was not comfortably satisfied that the players had been administered the substance.
Chloroform Ethyl chloride Diethyl ether Ethane and ethylene Laughing gas (nitrous oxide) Poppers (alkyl nitrites) Solvents and propellants (including propane, butane, freon, gasoline, kerosene, toluene) along with the fumes of glues containing them
Sources: en.wikipedia.org
=== United States === In the US, Good Manufacturing Practice (GMP) Regulations are based on the Code of Federal Regulations 21 CFR 210/211, and USP 1079. The US Drug Supply and Chain Security Act (DSCSA), was enacted by Congress on November 26, 2013 and outlines requirements to build electronic systems that identify and trace prescription drugs distributed in the US. By November 27th 2023, full electronic track & trace capability will be required for all partners in the supply chain.
==== F ==== Fesikh – a traditional Egyptian fish dish consisting of fermented salted and dried gray mullet, of the mugil family, a saltwater fish that lives in both the Mediterranean and the Red Seas.
==== Photolithography ==== Ultraviolet radiation is used for very fine resolution photolithography, a procedure wherein a chemical called a photoresist is exposed to UV radiation that has passed through a mask. The exposure causes chemical reactions to occur in the photoresist. After removal of unwanted photoresist, a pattern determined by the mask remains on the sample. Steps may then be taken to "etch" away, deposit on or otherwise modify areas of the sample where no photoresist remains. Photolithography is used in the manufacture of semiconductors, integrated circuit components, and printed circuit boards. Photolithography processes used to fabricate electronic integrated circuits presently use 193 nm UV and are experimentally using 13.5 nm UV for extreme ultraviolet lithography.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.